Ignite Creation Date:
2025-12-24 @ 12:46 PM
Ignite Modification Date:
2026-01-13 @ 5:15 PM
Study NCT ID:
NCT04449861
Status:
COMPLETED
Last Update Posted:
2024-11-27
First Post:
2020-05-06
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Small Cell Lung Carcinoma Extensive Disease | View |
Keywords: